Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Clinical trial NCT05758116 · COMPLETED

Trial details

NCT number: NCT05758116
Sponsor: Peking University Cancer Hospital & Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Consolidation Immunotherapy Radiotherapy or Sequential Chemoradiation

Start date: 2022-07-07
Primary completion: 2026-06-30
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.